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Background: The efficacy and safety of plant stanols added to food products as serum cholesterol lowering agents
have been demonstrated convincingly, but their effects on cholesterol metabolism and on serum non-cholesterol
sterols is less evaluated. The aim of this study was to assess the validity of serum non-cholesterol sterols and
squalene as bioindices of cholesterol synthesis and absorption, and to examine how the individual serum
non-cholesterol sterols respond to consumption of plant stanols.
Methods: We collected all randomized, controlled plant stanol ester (STAEST) interventions in which serum
cholestanol, plant sterols campesterol and sitosterol, and at least two serum cholesterol precursors had been
analysed. According to these criteria, there was a total of 13 studies (total 868 subjects without lipid-lowering
medication; plant stanol doses varied from 0.8 to 8.8 g/d added in esterified form; the duration of the studies varied
from 4 to 52 weeks). Serum non-cholesterol sterols were assayed with gas–liquid chromatography, cholesterol
synthesis with the sterol balance technique, and fractional cholesterol absorption with the dual continuous isotope
feeding method.
Results: The results demonstrated that during the control and the STAEST periods, the serum plant sterol/
cholesterol- and the cholestanol/cholesterol-ratios reflected fractional cholesterol absorption, and the precursor
sterol/cholesterol-ratios reflected cholesterol synthesis. Plant sterol levels were dose-dependently reduced by
STAEST so that 2 g of plant stanols reduced serum campesterol/cholesterol-ratio on average by 32%. Serum
cholestanol/cholesterol-ratio was reduced less frequently than those of the plant sterols by STAEST, and the
cholesterol precursor sterol ratios did not change consistently in the individual studies emphasizing the importance
of monitoring more than one surrogate serum marker.
Conclusions: Serum non-cholesterol sterols are valid markers of cholesterol absorption and synthesis even during
cholesterol absorption inhibition with STAEST. Serum plant sterol concentrations decrease dose-dependently in
response to plant stanols suggesting that the higher the plant stanol dose, the more cholesterol absorption is
inhibited and the greater the reduction in LDL cholesterol level is that can be achieved.
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The hypocholesterolemic effect of dietary plant sterol
supplementation was demonstrated for the first time in
humans in the 1950′s [1] and that of plant stanols in the
1980′s [2]. Today, several food products with added
plant sterols and plant stanols are used worldwide as a
dietary means to lower serum total and LDL cholesterol
concentrations by interfering with cholesterol absorption
[3,4]. Thus, in addition to the reduction in the serum
cholesterol concentration, these agents makes it possible
to evaluate cholesterol metabolism in response to inhi-
bition of cholesterol absorption.
The assessment of cholesterol absorption and syn-
thesis is laborious in clinical studies. For this reason,
serum non-cholesterol sterols have been examined as
relative markers of whole-body cholesterol metabolism
under steady state conditions with subjects consuming a
normal habitual diet. The levels of serum cholesterol
precursors (squalene, cholestenol, desmosterol, and la-
thosterol) reflect the activity of cholesterol synthesis,
and serum plant sterols (campesterol and sitosterol), and
cholestanol, reflect the absorption efficiency of choles-
terol. Their validity has been assessed by comparing the
synthesis marker values with those obtained with the
sterol balance technique [5-11] or with the evaluation of
hepatic 3-hydroxy-3-methyl-glutaryl-CoA reductase ac-
tivity [12], and the absorption marker values have been
validated with those obtained with continuous peroral or
peroral-intravenous isotopes and tracers [6-9,13,14]. For
particular, the cholesterol-standardized ratios of the rele-
vant serum markers were best associated with choles-
terol synthesis and absorption efficiency [6-9], and the
absorption marker/synthesis marker ratios with whole-
body cholesterol metabolism [6,7]. However, especially
during interventions and when only one serum marker
has been used, there have been inconsistencies in the re-
sults between the serum markers and absolute methods
[8,11]. In a recent cross-sectional study, e.g., serum plant
sterol/cholesterol-ratios did not correlate with fractional
cholesterol absorption [15]. In this study, the study
population of 175 hypercholesterolemic subjects was
divided into those with the lowest and highest cam-
pesterol/cholesterol ratio, and cholesterol absorption ef-
ficiency was measured with a single oral-intravenous
dose. Cholesterol absorption efficiency did not differ bet-
ween the groups. Of special interest was the very low
values of cholesterol absorption efficiency with a mean
of 24%, and only a few subjects reached the value of
50%, which is considered the average mean value among
different populations. The results were discussed by
Grundy [16] that there may be methodological reasons
related to the tracer or the single dose-method per se
causing these particularly low cholesterol absorption
values, which could explain the lack of association. Tothis end, the aim of this study was to assess the validity
of the cholesterol absorption and synthesis markers
during consumption of plant stanol-supplemented food
products. We also examined the changes in cholesterol
metabolism occurring in response to plant stanol inter-
ventions. Since in general the number of subjects in
single plant stanol interventions has been somewhat lim-
ited, we gathered together from PubMed all randomized
controlled studies in adults, in which at least two serum
synthesis markers, two serum plant sterols, and serum
cholestanol levels were analysed during plant stanol
intervention.Methods
Study population
With these criteria, 13 studies could be identified. These
included 868 subjects (414 men and 454 women) with
an age range from 20 to 73 years (Table 1). In eleven of
the studies, the subjects had mild to moderate hyper-
cholesterolemia [17-27]. In one study, the subjects were
type 1 diabetics [28], and another study focused on type
2 diabetics [29]. All subjects were without lipid-lowering
medication. The plant stanol dose varied from 0.8 to
8.8 g/d, and in all of the studies, the plant stanols were
consumed as their fatty acid esters. Two of the studies
were dose–response studies [23,27]. Six studies had a
cross-over and seven employed a parallel design. The
duration of plant stanol ester (STAEST) consumption
varied from 4 to 52 weeks.
All subjects gave their written informed consent. All
studies were performed according to the principles of the
Declaration of Helsinki. The Ethics Committees of the
University of Helsinki, Second Department of Medicine
(studies in ref 19,20,21,26,27,29), University of Kuopio
(studies in ref 17,22,23,24,28), the North Karelia Central
Hospital (study in ref 18), and Joint Ethics Committee of
the University of Turku and Turku University Central
Hospital (study in ref 25) had approved the study
protocols.Measurements
Serum concentrations of non-cholesterol sterols were
quantified from non-saponifiable serum-based materials
by capillary gas–liquid chromatography (GLC) (Agilent
6890 N Network GC System, Agilent Technologies,
Wilmington, DE) equipped with a 50 m long non-polar
Ultra 2 capillary column (5% phenyl-methyl siloxane;
Agilent Technologies, Wilmington, DE) with 5α-choles-
tane as internal standard [30]. Typical CVs at relevant
concentrations were: cholesterol 3.2%, cholestanol 2.7%,
desmosterol 6.0%, lathosterol 3.7%, campesterol 1.8%,
and sitosterol 2.4%. Serum non-cholesterol sterols are
given as concentrations (μg/dl) and in terms of ratios to
Table 1 LDL cholesterol and serum non-cholesterol sterol/cholesterol-ratios in different studies during STAEST consumption
First value: mean control value. In parenthesis: net relative change between STAEST and control values
Reference Design N Dose (g/d) Duration (wk) LDL-C Cholestanol Campesterol Sitosterol Squalene Cholestenol Desmosterol Lathosterol
Ref [18] Parallel 189 2 52 3.9 (−8%) 152 (−5%) 301 (−35%) 156 (−37%) 16 (−1%) 21 (7%) 81 (7%) 121 (7%)
Ref [24] Crossover 34 2 4 4.2 (−13%) 136 (−4%) 388 (−28%) 172 (−29%) 33 (22%) 16 (23%) 61 (11%) 164 (20%)
Ref [22] Parallel 76 2 10 3.5 (−9%) 155 (0%) 278 (−33%) 129 (−35%) 17 (4%) 17 (10%) 82 (9%) 129 (16%)
Ref [25] Parallel 190 2 12 3.9 (−9%) 151 (−4%) 284 (−29%) 142 (−32%) 18 (5%) 20 (19%) 98 (3%) 137 (19%)
Ref [28] Parallel 19 2 12 3.1(−16%) 178 (−4%) 483 (−24%) 198 (−23%) 17 (−30%) 18 (2%) 73 (0%) 95 (−3%)
Ref [19] Crossover 21 2.4 5 4.2 (−12%) 123 (−9%) 209 (−28%) 126 (−28%) 45 (11%) 18 (14%) 74 (15%) 175 (16%)
Ref [29] Crossover 11 3 6 3.8 (−9%) 94 (−10%) 241 (−43%) 110 (−42%) 31 (13%) 32 (10%) 109 (12%) 185 (14%)
Ref [21] Parallel 153 3 26 4.1 (−11%) 120 (−8%) 316 (−39%) 152 (−18%) 34 (2%) 18 (34%) 71 (11%) 176 (20%)
Ref [20] Crossover 22 3 7 3.7 (−17%) 127 (−9%) 301 (−41%) 147 (−22%) 36 (6%) 15 (19%) 91 (11%) 170 (12%)
Ref [26] Parallel 67 3.4 6 3.7 (−9%) 122 (−3%)1 346 (−48%)1 151 (−41%)1 33 (13%)1 19 (21%) 111 (27%) 203 (10%)
Ref [17] Parallel 49 8.8 10 3.2 (−17%) 157 (−2%) 337 (−62%) 164 (−48%) 15 (14%) 23 (20%) 86 (15%) 130 (30%)
Dose–response studies
Ref [27] Crossover 15 0.8 9 4.4 (−8%) 102 (4%)1 360 (−28%)1 163 (−24%)1 18 (14%)1 20 (−5%)1 69 (1%)1 162 (2%)1
2 6 4.5 (−15%) 102 (−2%)1 347 (−48%)1 158 (−41%)1 20 (−4%)1 22 (10%)1 28 (2%)1 160(16%)1
Ref [23] Crossover 22 0.8 4 4.4 (−2%) 141 (1%) 354 (−20%) 167 (−39%) 39 (9%) 21 (3%) 89 (4%) 133 (13%)
1.6 “(−6%) ”(−1%) ”(−35%) ”(−21%) ”(14%) ”(18%) ”(6%) ”(18%)
2.3 “(−10%) ”(1%) ”(−35%) ”(−34%) ”(21%) ”(22%) ”(7%) ”(19%)
3.1 “(−10%) ”(1%) ”(−39%) ”(−32%) ”(21%) ”(12%) ”(8%) ”(19%)
Plant stanols (g/d) added as plant stanol ester (STAEST) to the test mayonnaise [26,27], test spread [18-25,28,29] or test spread and test oat-based drink [17].
LDL is given as mmol/l, and squalene- and non-cholesterol sterol/cholesterol-ratios as 102 × μmol/mmol of cholesterol.
1Calculated from the mean values given in the publication.
Bold: p < 0.05 compared with control.
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Table 2 Correlation coefficients between serum
non-cholesterol sterol concentrations and the absolute
measurements of cholesterol metabolism
Serum squalene and
non-cholesterol
sterols, μg/dl
During
control
period
During plant stanol
ester intervention
Cholesterol synthesis,
mg/kg/d
Squalene −0.133 −0.053
Cholestenol 0.515** 0.592**
Desmosterol 0.325* 0.425**
Lathosterol 0.366* 0.378*
Fractional cholesterol
absorption, %
Cholestanol 0.627*** 0.558***
Campesterol 0.394* 0.411**
Sitosterol 0.448** 0.623***
The results from three studies [20,27,29] were combined.
*p < 0.05; **p < 0.01; ***p < 0.001.
N = 39.
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obtained from the same GLC run.
In the absolute metabolic studies, the participants took
a capsule containing 200 mg of Cr2O3,
3H-sitostanol,
and 14C-cholesterol three times a day with each major
meal for a week. During the last three days, stools were
collected and pooled for analysis of labels, neutral ste-
rols, and bile acids. The sterols and bile acids were mea-
sured with GLC [31], using the recovery of Cr2O3 or
labeled sitostanol for measurement of fecal flow. During
the week, the participants kept a food diary so that
energy, fat and cholesterol intakes could be quantified
with the assistance of a computerized program [32].
Statistics
All statistical analyses were performed with the SPSS for
Windows 19.0 statistics program (SPSS, Chicago, IL,
USA).
Since the separate studies differed in their design
(Table 1), the relative changes from the control values
were recalculated from original data except in two stud-
ies [26,27], in which the relative changes were calculated
from the mean values given in the publications. The
normal distribution of variables was confirmed before
further statistical analyses. When detecting the relation-
ships between the plant stanol dose and serum LDL
cholesterol and non-cholesterol sterols, nine studies with
hypercholesterolemic subjects [17-25] were included
into the further statistical analyses. Curve equations
were calculated by analysis of curve estimation and
ANCOVA with the study as a covariate. Pearson cor-
relation coefficients were also calculated. In addition,
when detecting the validity, i.e. the associations between
the simultaneous measurements of the serum non-
cholesterol sterols and absolute cholesterol synthesis and
absorption, the Pearson or Spearman correlation coeffi-
cients were calculated from the studies in which the
data was available [20,27,29]. A P value of <0.05 was
considered statistically significant.
Results
Serum non-cholesterol sterols as biomarkers of
cholesterol metabolism
In three studies (n = 39) [20,27,29], cholesterol metabolism
was evaluated with simultaneous measurements of frac-
tional cholesterol absorption, cholesterol synthesis, and
serum non-cholesterol sterols. During both the control
and STAEST periods, serum cholestanol, campesterol and
sitosterol concentrations (Table 2) and ratios to choles-
terol, shown for cholestanol/cholesterol- and sitosterol/
cholesterol-ratios in Figure 1 (Panels A and B), correlated
with fractional cholesterol absorption. Similarly, during
the control and STAEST periods, serum cholestenol, des-
mosterol, and lathosterol concentrations (Table 2) andratios to cholesterol (shown for cholestenol/cholesterol-
ratio in Figure 1 Panel C) correlated with cholesterol
synthesis. Serum squalene concentration or squalene/
cholesterol-ratio did not correlate with cholesterol synthe-
sis. The sitosterol/lathosterol-ratio correlated with frac-
tional cholesterol absorption during the control (r = 0.589,
p < 0.001) and STAEST periods (r = 0.662, p < 0.001), and
the corresponding values for cholesterol synthesis were
r = −0.532, p < 0.001 and r = −0.512, p < 0.001.
Relative changes in LDL cholesterol and serum
non-cholesterol sterol levels
In studies involving daily plant stanol intake ≥1.6 g, the
LDL cholesterol concentration was significantly reduced
(Table 1). Depending on the dose, the LDL cholesterol
level was reduced by 6% (plant stanols 1.6 g/d) up to
17% (plant stanols 8.8 g/d). The extent of the reduction
in LDL cholesterol correlated with the plant stanol dose
(r = 0.686, p = 0.014) (Figure 2 Panel A).
When compared to the controls, serum campesterol/
cholesterol-ratio and sitosterol/cholesterol-ratio were re-
duced in every study (Table 1). The reductions of plant
sterol/cholesterol-ratios were dose-dependent as shown
for the serum campesterol/cholesterol-ratio in Figure 2
Panel B (r = −0.919, p < 0.001). On the contrary, serum
cholestanol/cholesterol-ratio was reduced only in 5/17
trials (Table 1), and the reductions were not associated
with the plant stanol dose.
Regarding the serum cholesterol precursors, STAEST
consumption increased serum squalene/cholesterol-ratio
in 1/17 trials, the cholestenol/cholesterol-ratio in 9/17
trials, the desmosterol/cholesterol-ratio in 8/17 trials,
and the lathosterol/cholesterol-ratio in a clear majority
Figure 1 Cholesterol absorption and synthesis and serum biomarkers. Three studies [20,27,29] combined, n=39. Panel A: Fractional
cholesterol absorption (%) and serum cholestanol/cholesterol- ratio (102 × μmol/mmol of cholesterol) in 39 subjects during the control (closed
circles) and plant stanol ester (STAEST) (open circles) intervention periods. The results from three studies [20,27,29] were combined. Panel B:
Fractional cholesterol absorption (%) and serum sitosterol/cholesterol- ratio (102 × μmol/mmol of cholesterol) in 39 subjects during the control
(closed circles) and plant stanol ester (STAEST) (open circles) intervention periods. The results from three studies [20,27,29] were combined. Panel C:
Cholesterol synthesis (mg/kg/d) and serum cholestenol/cholesterol- ratio (102 × μmol/mmol of cholesterol) in 39 subjects during the control (open
circles) and plant stanol ester (STAEST) (open circles) intervention periods.
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cursor sterol to cholesterol ratios varied from 7 to 34%,
respectively, but there was extensive variation between
different studies even with the same plant stanol dose.
In two studies [17,28], all of the precursors remained
unchanged.
Discussion
The new results emerging from these analyses demon-
strate that during plant stanol consumption, serum non-
cholesterol sterol/cholesterol- ratios reflect the fractionalabsorption and whole-body synthesis of cholesterol. In
addition, serum absorption/synthesis marker ratios were
found to be valid markers of cholesterol metabolism
during plant stanol intervention. Second, serum levels of
plant sterols were dose-dependently reduced by plant
stanols. The serum cholestanol level was reduced less
frequently than the serum plant sterol levels during con-
sumption of STAEST. The cholesterol precursor sterols,
cholestenol, desmosterol and lathosterol, were not in-
creased similarly or were not increased at all in some
studies emphasizing the importance of adopting more
Figure 2 Changes in LDL cholesterol concentration and serum
campesterol/cholesterol-ratio and plant stanol dose. Panel A.
Change (%) in LDL cholesterol concentration from controls during
the different plant stanol doses in nine studies [17-25]. r = 0.686,
p = 0.014. Panel B. Change (%) in serum campesterol/cholesterol-ratio
from controls during the different plant stanol doses in nine studies
[17-25]. r = −0.919, p < 0.001.
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level was not related to cholesterol metabolism.
The study population contained all randomized con-
trolled plant stanol interventions in adults gathered from
PubMed, in which at least two serum synthesis markers,
two serum plant sterols, and serum cholestanol were
analysed. It turned out that the requirement for the non-
cholesterol sterols excluded other than our own studies.
In fact, 4 more studies could be retrieved from PubMed
containing serum lathosterol and plant sterol quantifica-
tions, but not the other non-cholesterol sterols.
If one adopts surrogate serum markers, there is always
the caveat that their validity should not be considered as
self-evident [8]. In situations when there is interference
with the homeostasis of cholesterol or the metabolism of
an individual marker, the serum value of the marker/s
no longer reflects cholesterol metabolism. Accordingly,
the metabolism of both cholesterol and the individualmarker need to be taken into consideration when inter-
preting the data. A classic example of potential misinter-
pretation is the fact that plant sterols cannot be used as
cholesterol absorption markers at the same time when
the subjects are consuming plant sterol-added products.
Similarly, when dietary intake of cholesterol was in-
creased by adding daily egg consumption, there was an
elevation in the serum lathosterol concentration, but this
no longer reflected cholesterol synthesis but instead the
increased intake of lathosterol present in the egg yolk
[11]. Even under baseline situations, the relative serum
markers may not reflect cholesterol metabolism. In vege-
tarians, cholesterol synthesis is known to be elevated as
compared with control subjects, but there was no in-
crease in the concentrations of the serum cholesterol
precursors [33].
In the present study, all serum cholesterol precursors
were unchanged in two studies. The subjects in one of
these studies were type 1 diabetics, and the precursor ra-
tios to cholesterol varied from −30% to +2%. Why in
type 1 diabetes cholesterol synthesis seems not to be ac-
tivated remains open and warrants further investigation.
Regarding the second study, the cholesterol precursors
were increased from 14% to 30%, but the increment did
not reach significance.
Cholestanol is a saturated derivative of cholesterol
produced by the liver. Its synthesis involves mainly a
rate-limiting oxidation pathway, but a smaller fraction is
also synthesized as a by-product of bile acid production
[34]. The dietary intake of cholestanol is minimal, less
than 2 mg/d [9], but if biliary secretion is impaired such
as in cholestasis, then serum cholestanol values rapidly
increase and no longer reflect the absorption efficiency
of cholesterol [35]. Even though the serum cholestanol
concentration and the cholestanol/cholesterol-ratio cor-
related with fractional cholesterol absorption during
STAEST, in the individual studies the cholestanol/chol-
esterol-ratio was less frequently reduced than the serum
plant sterol/cholesterol-ratios.
In the present analysis, the relative LDL cholesterol re-
duction varied from 6 to 17% depending on the plant
stanol dose used in the different studies. Similarly, the
relative reduction for campesterol/cholesterol-ratio va-
ried from 35 to 62%. One can calculate that a 2 g plant
stanol dose can achieve about a 10% reduction in
the LDL cholesterol concentration and a 32% decrease
in the serum campesterol/cholesterol-ratio (Figure 2).
Accordingly, the change in serum campesterol/choles-
terol-ratio can also be utilized as an indicator of the
compliance of the STAEST intake. An earlier study de-
monstrated that when LDL cholesterol was lowered by
10% with plant stanols, fractional cholesterol absorption
was reduced by 45% and the serum campesterol/choles-
terol-ratio by 34% (p < 0.05 for all) [36], which is the
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values suggest that approximately a four-fold inhibition
in cholesterol absorption efficiency is needed to achieve
a unit decrease in the LDL cholesterol concentration.
Conclusions
In conclusion, serum non-cholesterol sterols are valid
markers of cholesterol absorption and synthesis during
cholesterol absorption inhibition with plant stanol ester.
Serum levels of non-cholesterol sterols did not change
consistently in the individual studies emphasizing the
importance of utilizing more than one surrogate serum
marker. Serum plant sterols decrease dose-dependently
after consumption of plant stanols suggesting that the
higher the plant stanol dose, the more cholesterol ab-
sorption will be inhibited and the more efficiently the
LDL cholesterol levels will be reduced.
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